Syros to Present New Data from Phase 1 Clinical Trial of SY-5609 in Oral Presentation at ESMO Congress 2021
September 13 2021 - 7:00AM
Business Wire
Management to Host Conference Call on Monday,
September 20, 2021 at 4:00 p.m. ET
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development
of medicines that control the expression of genes, today announced
that it will present new data from the dose-escalation portion of
the Phase 1 clinical trial of SY-5609, its highly selective and
potent oral cyclin-dependent kinase 7 (CDK7) inhibitor, at the ESMO
Congress 2021, taking place virtually September 16-21, 2021. The
oral presentation will include safety, tolerability, and initial
clinical activity data for SY-5609 in patients with breast,
colorectal, lung, ovarian and pancreatic cancers, as well as in
patients with solid tumors of any histology harboring Rb pathway
alterations.
In separate poster presentations, Syros will present new
preclinical data evaluating the antitumor and pharmacodynamic
activity of intermittent dosing regimens for SY-5609 in ovarian
cancer models, as well as new preclinical data evaluating antitumor
activity of SY-5609 as a single agent and in combination with
chemotherapy in KRAS-mutant models.
The abstracts for the two poster presentations are now available
online on the ESMO conference website at:
https://www.esmo.org/meetings/esmo-congress-2021/abstracts, and the
presentations will become available for on-demand viewing starting
September 16 at 08:30 CEST (September 16 at 2:30 a.m. ET). The
abstract for the oral presentation on the Phase 1 dose-escalation
data will remain embargoed until September 17 at 00:05 CEST
(September 16 at 6:05 p.m. ET).
Details of the oral presentation are as follows:
Presentation Title: Tolerability and Preliminary Clinical
Activity of SY-5609, a Highly Potent and Selective Oral CDK7
Inhibitor, in Patients with Advanced Solid Tumors Session Date
& Time: Monday, September 20, 17:30-18:30 CEST (11:30-12:30
p.m. ET) Presentation Time: 17:55-18:00 CEST (11:55-12:00
p.m. ET) Session Title: Mini Oral Session: Developmental
Therapeutics Presenter: Manish Sharma, M.D., START Midwest
Abstract Number: 518MO
Details of the poster presentations are as follows:
Presentation Title: Preclinical Evaluation of
Intermittent Dosing Regimens on Antitumor and PD Activity of
SY-5609, a Potent and Selective Oral CDK7 Inhibitor, in Ovarian
Cancer Xenografts Abstract Number: 14P Presentation
Title: SY-5609, a Highly Potent and Selective Oral CDK7
inhibitor, Exhibits Robust Antitumor Activity in Preclinical Models
of KRAS Mutant Cancers as a Single Agent and in Combination with
Chemotherapy Abstract Number: 13P
Conference Call Information
Syros will host a conference call on Monday, September 20, 2021
at 4:00 p.m. ET to discuss the new clinical and preclinical data
for SY-5609, which will be presented at the ESMO Congress 2021.
To access the live conference call, please dial 866-595-4538
(domestic) or 636-812-6496 (international) and refer to conference
ID 4648345. A webcast of the call will also be available on the
Investors & Media section of the Syros website at
www.syros.com. An archived replay of the webcast will be available
for approximately 30 days following the conference call.
About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the
expression of genes. Based on its unique ability to elucidate
regulatory regions of the genome, Syros aims to develop medicines
that provide a profound benefit for patients with diseases that
have eluded other genomics-based approaches. Syros is advancing a
robust clinical-stage pipeline, including: tamibarotene, a
first-in-class oral selective RARα agonist in RARA-positive
patients with higher-risk myelodysplastic syndrome and acute
myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in
patients with acute promyelocytic leukemia; and SY-5609, a highly
selective and potent oral CDK7 inhibitor in patients with select
solid tumors. Syros also has multiple preclinical and discovery
programs in oncology and monogenic diseases.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210913005090/en/
Media Contact: Naomi Aoki Syros Pharmaceuticals
617-283-4298 naoki@syros.com
Investor Contact: Hannah Deresiewicz Stern Investor
Relations, Inc. 212-362-1200 hannah.deresiewicz@sternir.com
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Apr 2023 to Apr 2024